Andreas Maetzel Sells 5,000 Shares of Kalvista Pharmaceuticals Inc (KALV) Stock
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) insider Andreas Maetzel sold 5,000 shares of the firm’s stock in a transaction on Friday, April 5th. The stock was sold at an average price of $30.00, for a total transaction of $150,000.00. Following the completion of the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at approximately $150,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
NASDAQ:KALV traded down $0.74 during midday trading on Tuesday, hitting $28.57. The company’s stock had a trading volume of 87,400 shares, compared to its average volume of 114,499. Kalvista Pharmaceuticals Inc has a fifty-two week low of $7.73 and a fifty-two week high of $34.92. The company has a market cap of $505.60 million, a PE ratio of -18.67 and a beta of 2.48.
Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.22. Kalvista Pharmaceuticals had a negative net margin of 70.08% and a negative return on equity of 19.12%. The company had revenue of $3.89 million during the quarter, compared to analyst estimates of $3.97 million. On average, research analysts anticipate that Kalvista Pharmaceuticals Inc will post -1.43 EPS for the current year.
Several equities research analysts have recently commented on KALV shares. Cantor Fitzgerald reiterated a “buy” rating and set a $32.00 price objective on shares of Kalvista Pharmaceuticals in a research note on Friday, December 14th. BidaskClub downgraded Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. TheStreet upgraded Kalvista Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Thursday, December 20th. Zacks Investment Research raised Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a research report on Wednesday, January 2nd. Finally, ValuEngine raised Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $28.60.
COPYRIGHT VIOLATION WARNING: “Andreas Maetzel Sells 5,000 Shares of Kalvista Pharmaceuticals Inc (KALV) Stock” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/andreas-maetzel-sells-5000-shares-of-kalvista-pharmaceuticals-inc-kalv-stock/2951469.html.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
See Also: Initial Public Offering (IPO)
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.